Health Care & Life Sciences » Biotechnology | BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
17,331.00
13,608.00
48,257.00
26,353.00
25,186.00
20,653
Cost of Goods Sold (COGS) incl. D&A
402.00
210.50
1,896.00
2,699.00
1,702.00
856
Gross Income
16,929.00
13,397.50
46,361.00
23,654.00
23,484.00
19,797
SG&A Expense
42,646.00
59,168.50
85,805.00
72,261.00
80,895.00
103,017
EBIT
25,717.00
45,771.00
-
48,607.00
57,411.00
83,220
Unusual Expense
294.00
5,487.00
564.00
843.00
821.00
11,108
Non Operating Income/Expense
-
-
1,667.00
11.00
1.00
943
Interest Expense
4,778.00
4,998.00
5,200.00
6,487.00
8,565.00
10,117
Pretax Income
30,108.00
45,189.00
43,019.00
55,144.00
65,782.00
101,252
Consolidated Net Income
30,108.00
45,189.00
43,019.00
55,144.00
65,782.00
101,252
Net Income
30,108.00
45,189.00
43,019.00
55,144.00
65,782.00
101,252
Net Income After Extraordinaries
30,108.00
45,189.00
43,019.00
55,144.00
65,782.00
101,252
Net Income Available to Common
30,108.00
45,189.00
43,019.00
55,144.00
65,782.00
101,252
EPS (Basic)
0.55
0.68
0.59
0.75
0.78
0.98
Basic Shares Outstanding
55,216.00
66,773.00
72,901.00
73,699.00
84,451.00
103,185
EPS (Diluted)
0.55
0.68
0.59
0.75
0.78
0.98
Diluted Shares Outstanding
55,216.00
66,773.00
72,901.00
73,699.00
84,451.00
103,185
EBITDA
25,413.00
45,594.00
39,264.00
48,124.00
56,707.00
82,450
Non-Operating Interest Income
93.00
93.00
522.00
782.00
1,014.00
2,250

About BioCryst Pharmaceuticals

View Profile
Address
4505 Emperor Boulevard
Durham North Carolina 27703
United States
Employees -
Website http://www.biocryst.com
Updated 07/08/2019
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.